九月的最后两周,减重药又成医药圈讨论热门。其中,手握药王司美格鲁肽的丹麦制药巨头诺和诺德全球裁员9000人,掀开了全球减重药市场重构的一角:“一家独大”的黄金时代谢幕,“诸神混战”的下半场拉开序幕。按照诺和诺德9月10日公布的裁员计划,全球约9000个岗位将受波及,约5000个岗位在丹麦,调整范围遍布各个部门,包括支持部门和总部职能。关于中国区的裁员计划,还没有更多官方消息透露。一份业界流传的内部...
Source Link九月的最后两周,减重药又成医药圈讨论热门。其中,手握药王司美格鲁肽的丹麦制药巨头诺和诺德全球裁员9000人,掀开了全球减重药市场重构的一角:“一家独大”的黄金时代谢幕,“诸神混战”的下半场拉开序幕。按照诺和诺德9月10日公布的裁员计划,全球约9000个岗位将受波及,约5000个岗位在丹麦,调整范围遍布各个部门,包括支持部门和总部职能。关于中国区的裁员计划,还没有更多官方消息透露。一份业界流传的内部...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.